Inhibitor Therapeutics, Inc. - FORM 10-K - EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - February 17, 2017

Attached files

file filename
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Inhibitor Therapeutics, Inc.d306040dex231.htm
EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Inhibitor Therapeutics, Inc.d306040dex321.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Inhibitor Therapeutics, Inc.d306040dex312.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Inhibitor Therapeutics, Inc.d306040dex311.htm
EX-10.16 - AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGRREMENT - Inhibitor Therapeutics, Inc.d306040dex1016.htm
EX-10.11 - 1ST AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND GARRISON J. HASARA - Inhibitor Therapeutics, Inc.d306040dex1011.htm
EX-10.6 - 2ND AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND NICHOLAS J. VIRCA - Inhibitor Therapeutics, Inc.d306040dex106.htm
10-K - FORM 10-K - Inhibitor Therapeutics, Inc.d306040d10k.htm

Exhibit 32.2

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(18 U.S.C. 1350)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), the undersigned officer of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of such officer’s knowledge and belief, that:

(1) The Annual Report on Form 10-K for the year ended December 31, 2016 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Form 10-K fairly presents, in all materials respects, the financial condition and results of operations of the Company.

 

Date: February 17, 2017      

/s/ Garrison J. Hasara

      Garrison J. Hasara, Chief Financial Officer and Treasurer

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Securities Exchange Act.

Inhibitor Therapeutics, Inc. Reports